" class="no-js "lang="en-US"> Jehan Liénart - Medtech Alert
Monday, September 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Jehan Liénart

Jehan Liénart

About Jehan Liénart

Experienced Consul with a demonstrated history of working in the pharmaceuticals industry. Strong community and social services professional skilled in Negotiation, Pharmaceutics, Entrepreneurship, Sales Management, and Management.

Related Story

News

 Vésale Bioscience Named Most Innovative Start-up in Life Sciences in Europe at Tenth Edition of BioFIT | Pharmtech Focus

Vésale Bioscience Named Most Innovative Start-up in Life Sciences in Europe at Tenth Edition of BioFIT

December 10 2021

Vésale Bioscience, a biotech company specializing in phage therapy, with a particular focus on research […]